| Item Type | Name |
|
Concept
|
Apolipoproteins B
|
|
Concept
|
Apolipoproteins
|
|
Concept
|
Apolipoproteins E
|
|
Concept
|
Apolipoproteins C
|
|
Concept
|
Apolipoprotein A-I
|
|
Concept
|
Apolipoprotein B-100
|
|
Concept
|
Apolipoprotein E4
|
|
Concept
|
Apolipoprotein C-III
|
|
Concept
|
Apolipoprotein C-II
|
|
Academic Article
|
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.
|
|
Academic Article
|
The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study.
|
|
Academic Article
|
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
|
|
Academic Article
|
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
|
|
Academic Article
|
Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
|
|
Academic Article
|
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study.
|
|
Academic Article
|
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.
|
|
Academic Article
|
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
|
|
Academic Article
|
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.
|
|
Academic Article
|
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial.
|
|
Academic Article
|
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
|
|
Academic Article
|
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
|
|
Academic Article
|
A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease.
|
|
Academic Article
|
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
|
|
Academic Article
|
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.
|
|
Academic Article
|
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
|
|
Academic Article
|
Global risk management in patients with type 2 diabetes mellitus.
|
|
Academic Article
|
Biologic therapies for dyslipidemia.
|
|
Academic Article
|
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
|
|
Academic Article
|
Novel targets that affect high-density lipoprotein metabolism: the next frontier.
|
|
Academic Article
|
High-density lipoproteins: marker of cardiovascular risk and therapeutic target.
|
|
Academic Article
|
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
|
|
Academic Article
|
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
|
|
Academic Article
|
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
|
|
Academic Article
|
Apolipoprotein measurements: is more widespread use clinically indicated?
|
|
Academic Article
|
Apolipoprotein A-I therapy promise, challenges, and disappointment.
|
|
Academic Article
|
The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.
|
|
Academic Article
|
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.
|
|
Academic Article
|
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
|
|
Academic Article
|
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
|
|
Academic Article
|
Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.
|
|
Academic Article
|
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein.
|
|
Academic Article
|
Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women.
|
|
Academic Article
|
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients.
|
|
Academic Article
|
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
|
|
Academic Article
|
Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure?
|
|
Academic Article
|
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
|
|
Academic Article
|
Diagnosis and treatment of familial hypercholesterolaemia.
|
|
Academic Article
|
Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology.
|
|
Academic Article
|
ETC-1002: a future option for lipid disorders?
|
|
Academic Article
|
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination.
|
|
Academic Article
|
Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
|
|
Academic Article
|
Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids.
|
|
Academic Article
|
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
|
|
Academic Article
|
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
|
|
Academic Article
|
The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
|
|
Academic Article
|
Can We Cure Atherosclerosis?
|
|
Academic Article
|
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
|
|
Academic Article
|
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.
|
|
Academic Article
|
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
|